ArticleNature cancer2023
An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 137 papers.
0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
21.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 140 citations in OpenAlex.
- A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.Nature communications · 2025Trial
- The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.Nature communications · 2024Trial
- Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026Review
- Inflammation as a central driver in AML pathogenesis and therapy resistance.Science China. Life sciences · 2026Review
- Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia.HemaSphere · 2026Article
- Article
- PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy.Journal for immunotherapy of cancer · 2026Article
- FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.Blood · 2026Article
- Article
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- SIX1 drives acute myeloid leukemia progression by reprogramming glycolytic metabolism and impairing CD8⁺ T-cell effector function.Immunologic research · 2026Article
- Decoding the actionable potential of ribosome biogenesis in acute myeloid leukemia.Haematologica · 2026Article
- Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape.The Journal of clinical investigation · 2026Article
- PROTAC-mediated targeting of IKKβ and NR4A1 for AML therapy.Oncogene · 2026Article
- Inflammatory immune modulators of AML lung infiltration and respiratory failure.Nature immunology · 2026Article
- Single-cell RNA sequencing reveals chemotherapy-induced apoptosis in acute myeloid leukemia via B cell depletion and M2 to M1 macrophage repolarization.Human genomics · 2026Article
- Distinct stem cell identities converge into shared erythroid stress in ERCC6L2 disease and Shwachman-Diamond syndrome.HemaSphere · 2026Article
- Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.Nature cancer · 2026Article
- A gene signature derived from leukemia associated macrophages provides a compelling risk stratification for human AML patients.Biomarker research · 2026Article
- Bioinformatics-driven dissection of PANoptosis-related molecular subtypes and tumor immune microenvironment heterogeneity in pediatric acute myeloid leukemia.Annals of hematology · 2026Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
22 authors at 7 institutions in 2 countries.
Audrey Lasry *Department of Pathology, New York University School of Medicine, New York, NY, USA.
Bettina Nadorp *Department of Pathology, New York University School of Medicine, New York, NY, USA.
Maarten FornerodDepartment of Cell Biology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-6166-3030
Deedra NicoletThe Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA.
Huiyun WuDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Christopher J WalkerThe Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA.
Zhengxi SunDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Matthew T WitkowskiDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0003-1434-4288
Anastasia N TikhonovaDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0001-6712-1606
Maria Guillamot-RuanoDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Geraldine CayananDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Anna YeatonDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Gabriel RobbinsDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0002-4447-0667
Esther A ObengDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-8691-7439
Aristotelis TsirigosDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0002-7512-8477
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John C ByrdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Stanley PoundsDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-9167-2114
William L CarrollDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0003-1550-4167
Tanja A GruberDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. tagruber@stanford.edu.ORCID 0000-0003-1072-7257
Ann-Kathrin EisfeldThe Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH, USA. ann-kathrin.eisfeld@osumc.edu.ORCID 0000-0001-6442-1419
Iannis AifantisDepartment of Pathology, New York University School of Medicine, New York, NY, USA. ioannis.aifantis@nyulangone.org.ORCID 0000-0001-6857-1035
New York University · USSt. Jude Children's Research Hospital · USThe Ohio State University · USDana-Farber Cancer Institute · USErasmus MC · NLStanford Medicine · USUniversity of Cincinnati · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MVaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MXenotransplant and Genome Editing CoreU54DK126108 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Daniel Starczynowski, YI ZHENG · 2021 to 2026
$5.0MDissecting innate immune signaling in pre-leukemia evolutionR01CA271455 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Iannis Aifantis, Daniel Starczynowski · 2022 to 2026
$3.2MTargeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7MUnderstanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AMLR01CA262496 · NCI · OHIO STATE UNIVERSITY · PI Ann-Kathrin Eisfeld, Elaine R. Mardis · 2022 to 2026
$2.6MRegulation of emergency hematopoiesis by the ubiquitin-proteasome systemR01HL159175 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI AIFANTIS, IANNIS, BUSINO, LUCA · 2021 to 2024
$2.5MMechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5MNCI NIH HHS K22 CA258520NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA262496NCI NIH HHS R01 CA271455NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171NHLBI NIH HHS R01 HL159175NIDDK NIH HHS U54 DK126108
Abstract
Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and limited treatment options. Here we provide a comprehensive census of the bone marrow immune microenvironment in adult and pediatric patients with AML. We characterize unique inflammation signatures in a subset of AML patients, associated with inferior outcomes. We identify atypical B cells, a dysfunctional B-cell subtype enriched in patients with high-inflammation AML, as well as an increase in CD8
Indexed as
Leukemia, Myeloid, AcuteAdultBone MarrowChildHumansInflammationRisk AssessmentT-Lymphocytes, RegulatoryTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.